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76 Poster Session IIntroduction: Cell dose is a critical factor influencing engraft-
ment and outcomes of cord blood (CB) transplantation. Rate of re-
jection is high (12–20%) in many pediatric non-malignant
disorders. Also, GVHD is not beneficial; 10–30% patients develop
acute GVHD $ grade II using bone marrow (BM) as the stem cell
source, while chronic GVHD occurs in 5–15% cases. During an
HLA-ID sibling donor (MSD)hematopoietic stem cell transplanta-
tion (HCT), the limited CB cell dose can be boosted by a BM har-
vest. We retrospectively studied the engraftment rate, incidence of
GVHD and outcomes of co-infusion of MSD CB and BM. Mate-
rials and Methods: 13 children underwent HCT after combining
CB and BM from their MSDs at multiple institutions between 6/
1998 to 6/2006. The data was collected from the Oakland Sibling
Cord Blood Registry database. Median age of patients was 5.9 years
(range: 2.2–13 yrs). HCT was performed for Thalassemia (n 5 7),
Sickle cell anemia (n 5 4), SAA and Hurler’s syndrome (1 each).
Most patients (9) received Busulfan, Cytoxan and ATG for condi-
tioning. The main reason for boosting CB with BM was a low
CD341 cell content in the CB unit. Median CB CD341 was 1.1
 105/kg (0.1–4.4  105/kg). The marrow cell dose ranged from
0.9  108/kg-2.6  108 TNC/kg recipient weight. Results: All 13
patients achieved donor engraftment. The median time to neutro-
phil recovery was 18 days (range: 12 to 27) and for platelet engraft-
ment was 29 days (range: 18 to 90). None of the patients developed
acute GVHD $ grade 2 and no chronic GVHD was reported.
There was no TRM and all patients remain alive with a median fol-
low-up of 1402 days (467–3406 days). None of the patients have re-
quired transfusions post-transplant and the patient with Hurler
syndrome has maintained 100% donor chimerism. Conclusions:
1. There were no engraftment failures after co-infusion compared
to the higher historical rates reported after HCT using BM or
CB alone in non-malignant conditions.
2. The addition of BM to boost the cellular content promoted rapid
engraftment. There was a more rapid rate of recovery of neutro-
phils and platelets particularly, compared to conventional CB
transplantation, which might have reduced TRM.
3. No acute or chronic GVHD was noted after co-infusion inspite
of increased cell dose. Combining CB to BMmay have mitigated
the risk of GVHD.
4. Co-infusion of BM and CB is a feasible and effective strategy in
improving outcomes of HCT in non-malignant disorders, when
available in the MSD setting.Table 1. Patterns of chimerism
Chimerism
pattern N
% of donor
CD31 cells,
day 1 30
% of donor
cells in whole
blood, day 1 30
subsequent %
of donor
CD31 cells
subsequent %
of donor cells
in whole blood
Early complete
donor
chimerism (CDC)
2 $99 % $99% $99% $99%
CDC achieved later 4 26–91% 87–99% $99% by
7 months
post transplant
$99% by
7 months
post transplant
Increasing and
concordant
CD31 and WhBCh
5 .50% . 90% .80% by
7 months post
transplant
.90% by
7 months
post transplant
Low or fluctuating
CD31 chimerism,
stable WhBCh
8 8–77% 74–99% low or
.20% decline
with subsequent
gradual increase
to 45–95%
stable, 73–99%
Declining WhBCh,
low or fluctuating
CD31 chimerism,
discordant
CD31 and WhBCh
4 7–78% 79–99% low or
. 20% decline
with gradual
increase to
37–55%
decline over
time to 28–74%
Precipitous decline
in CD31 and WhBCh
2 63%; 1% 99%; 70% down to
0% by 2 months
post transplant
down to 0% and
13% by 2 months
post transplant205
LOW MOLECULAR WEIGHT HEPARIN (LMWH) PROPHYLAXIS (PPX) IN
PEDIATRIC RECIPIENTS FOLLOWING PEDIATRIC MYELOABLATIVE
STEM CELL TRANSPLANT (SCT) AT HIGH RISK FOR SINUSOIDAL OB-
STRUCTIVE SYNDROME (SOS): IS IT SAFE AND DOES IT MAKE A DIFFER-
ENCE?
Rogoza, K.1, Bhatia, M.2, Baldinger, L.1, van de Ven, C.2, Militano, O.1,
Qualter, E.1, Cairo, M.S.2. 1Morgan Stanley’s Children’s Hospital of
NewYork-Presbyterian, New York, NY; 2Columbia University, New
York, NY.
SOS is a clinical syndrome following SCTof jaundice, painful he-
patomegaly and weight gain with an incidence of 20% (2–54%) and
a mortality rate of 30–50%. The Children’s Group reported a 10%
incidence of SOS in pediatric recipients (n 5 2725; mild:3.1%,
moderate:5.2%, severe:2%) with a 1.8% mortality rate (Neider,
ASBMT, 2007). Risk factors include hepatitis, transaminitis, he-
patic irradiation, second SCT, and myeloablative conditioning reg-
imens (busulfan .8 mg/kg, cyclophosphamide $120 mg/kg, TBI,
and/or melphalan$135 mg/m2). We have demonstrated the safety
and efficacy of unfractionated heparin for SOS PPX in pediatric
SCT recipients (Rosenthal/Cairo et al, BMT, 1996). Simon et al
(BMT, 2001) demonstrated the use of LMWH for SOS PPX in
adult recipients. In this study we investigated the use of LMWH
in patients (pts) at high risk ($ 2 risk factors) for SOS to determine
if there was a difference in incidence of SOS compared with stan-
dard risk recipients not receiving LMWH. 36 pts at very high risk
for SOS received LMWH (1 mg/kg SQ) from 1st day of condition-
ing until D 1 21 post SCT. Median age 8.1 years (0.3–21, 23M/13F). Anti-Factor Xa levels were maintained between 0.3–0.5 Iu/
ml. Platelets were kept .30,000/mm3. Hemorrhage was graded
by NCI CTCAE 3.0. SOS was graded according to McDonald cri-
teria (Ann Int, 1993). 52 pts with\2 risk factors did not receive
LMWH PPX. Median age 8.6 years (0.3–23, 26M/26F). Of those
receiving LMWH, 4 pts developed SOS (mild, n 5 1; moderate,
n5 1; severe, n5 2). There were no hemorrhagic Grade III/IV tox-
icities. In the comparative standard risk group, 2 pts developed
moderate SOS. The probability of developing SOS in the high-
risk LMWH vs. comparison group was not significantly different:
11.1% (CI 95: 0.8–21.4) vs. 3.8%(CI95: 0–9.1), p 5 0.17 (Fig 1).
The OS in the LMWH group (50.3%) vs. the comparison standard
risk group (49.4%) was not statistically significant. No significant
difference in OS was observed in each sub-group who developed
SOS. These results suggest that LMWH can be administered safely
and may be effective SOS PPX in very high-risk pediatric SCT re-
cipients. A randomized double blind international trial comparing
LMWH vs. placebo will be required to determine the efficacy of
LMWH in pediatric SCT recipients at high risk of post SCT
SOS.206
FLUCTUATIONS IN CD31 SUBSET CHIMERISM ARE NOT PREDICTIVE OF
GRAFT REJECTION IN CHILDREN UNDERGOING TRANSPLANT FOR NON-
MALIGNANT DISORDERS
Ozyurek, E.1, Cowan, M.2, Koerper, M.2, Baxter-Lowe, L.A.3, Horn, B.2.
1Ondokuz University, Samsun, Turkey; 2University of California San
Francisco, San Francisco, CA; 3University of California San Francisco,
San Francisco, CA.
In non-malignant disorders, complete donor hematopoietic chi-
merism is not required for reversal or cure of underlying disease.
However, the risk of graft rejection may correlate with the degree
of donor chimerism.We postulated that the degree of donor chime-
rism, in particular, in CD31 cell lineage, may predict durability of
engraftment.
Retrospective chimerism data from 25 children undergoing 1st
transplant at UCSF between 2001 and 2007 were analyzed. The di-
agnoses included: bone marrow failure syndromes (N 5 9); meta-
bolic disorders (N 5 7); immunodeficiencies (N 5 6);
hemoglobinopathies (N 5 2); and autoimmune disorders (N 5 1).
